The latest guidance is out for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs (DMARDs). It’s aimed at primary and secondary care practitioners managing patients with rheumatic disease in the UK.
Significant updates include:
(1) Harmonisation of monitoring schedules, recommending that all DMARDs that require laboratory monitoring follow the same frequency of testing
(2) More nuanced discussion of the use of methotrexate in lung disease is provided, drawing from the two large meta-analyses recently published.
(3) Significant change is made regarding the evaluation of retinal toxicity for hydroxychloroquine users:
Lead author Dr James Galloway, Senior Clinical Lecturer at King’s College London says:
“These updates have two major focuses: firstly, streamlining monitoring schedules wherever possible, given the myriad of different regimens across drugs, and most of the schedule variations were somewhat arbitrary in their origins; second, to review and incorporate the evidence base available, acknowledging several key publications that have emerged since the first guidance.…
Read more of this article
The National Osteoporosis Society is launching “A Message to My Younger Self” – an awareness campaign about keeping bones strong and health. It begins on 12th April 2017 and runs through to World Osteoporosis Day on 20th October. NOS want the generations to have a conversation about healthy bones, to talk about the steps that can be taken to make sure bones are strong, and to give a voice to the millions of people with the condition.
British Society for Rheumatology publishes updated guideline non-biologic disease modifying anti-rheumatic drugs (DMARDs).